Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Typhoid, paratyphoid envelope protein vaccine

A technology for outer membrane protein and paratyphoid fever, applied in the field of vaccines, can solve the problems of irregular stability of live attenuated vaccines, limited usage, and unsatisfactory effects.

Active Publication Date: 2009-12-23
BEIJING ZHIFEI LVZHU BIOPHARM
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the 1960s and 1970s, clinical studies of inactivated whole-cell vaccines were carried out in many countries, but the side effects were relatively large and the effect was not satisfactory, so it has been discontinued.
Streptomycin-dependent typhoid mutant live vaccines have poor reproductive ability in normal humans, and the effect after immunization is unsatisfactory, and the freeze-dried vaccine has completely lost its protective power, and research has also stopped
The typhoid Ty21a live attenuated vaccine has undergone a large number of clinical trials and has been proven to be one of the safest and most effective typhoid vaccines without serious side effects. However, some scholars have raised the following controversial issues about the Ty21a mutant strain for a long time: The genetic stability of the attenuated strain cannot be determined, and it is speculated that its virulence may return to the ancestor; the mutation of the galE gene cannot fully explain the attenuation mechanism of the vaccine; there are mutations in other unknown parts of the gene; the freeze-dried dosage form is attenuated The irregular stability of live vaccines, too many oral vaccinations, and severe gastrointestinal reactions are unacceptable, and the current use is limited
The above research results show that typhoid outer membrane protein antigens can induce the body to produce functional antibodies, and more than half of the experimental animals can resist 10-500LD 50 For the challenge of a dose of live bacteria, the dose of the immunogen used in the above-mentioned experiments is mostly 20-100 micrograms per bird, and the dose of the immunogen used in the experiment is relatively large. From the test results, it is difficult to infer the dose for human use. The selection of references has limited significance, and the current typhoid vaccine was not selected as a positive control when conducting animal experiments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Typhoid, paratyphoid envelope protein vaccine
  • Typhoid, paratyphoid envelope protein vaccine
  • Typhoid, paratyphoid envelope protein vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] The preparation method of Bacillus typhi outer membrane protein:

[0048] Open typhoid strains, inoculate in semi-solid medium, then inoculate in 3L seed medium, place the culture bottle on a constant temperature shaker at 37°C, shake at 200 rpm, and cultivate until A 650 = 0.6~1.0, transfer to a 50L automatic bioreactor containing 30L medium, cultivate until just after the logarithmic growth phase (about 8~12 hours), add formaldehyde solution with a final concentration of 1% to sterilize 1 hours, 4 ° C, 11000 rpm centrifugation, typhoid bacteria (about 200 ~ 300 grams of wet weight), add 2000 ml of 100mM TRIS-HCl (pH 7.5 ~ 8.5, containing 20mM EDTA) buffer to dissolve, electric mixer stirring, Rotate at about 500 rpm, stir for 30 minutes to fully suspend the bacteria, then add 500 ml of 2.5% sodium deoxycholate (DOC) solution, adjust the rotating speed to about 250-300 rpm, stir at 4°C for 24-72 Hour.

[0049] Take out the typhoid bacterial suspension from the 4°C fr...

Embodiment 2

[0057] Preparation method of Bacillus paratyphi A outer membrane protein

[0058] Open the strains of paratyphoid A, inoculate in semi-solid medium, then inoculate in 3L seed medium, place the culture bottle on a constant temperature shaker at 37°C, 200 rpm, and cultivate to A 650 = 0.6 to 0.8, transfer to a 50L fully automatic bioreactor containing 30L medium, cultivate until just after the logarithmic growth phase (about 8 to 14 hours), add a final concentration of 1.5% formaldehyde solution to sterilize 1 Centrifuge at 4°C and 11,000 rpm for 1 hour to obtain typhoid thallus (about 200-250 g wet weight), add 2000 ml of 100 mM TRIS-HCl (pH 7.5-8.5, containing 20 mM EDTA) buffer to dissolve, stir with an electric mixer, Rotate at about 500 rpm, stir for 30 minutes, then add 500 ml of 2.5% Zwittergen-3-14 solution, adjust the rotating speed to about 250-300 rpm, and stir at 4°C for 24-72 hours.

[0059] Take out the bacterial cell suspension from the 4°C freezer, centrifuge at...

Embodiment 3

[0063] Preparation method of Bacillus paratyphi b outer membrane protein

[0064] Open the strain of paratyphoid B, inoculate it in a semi-solid medium, then inoculate it in a 3L seed medium, place the culture bottle on a constant temperature shaker at 37°C, 200 rpm, and cultivate it until A 650 = 0.4 to 0.8, transfer to a 50L fully automatic bioreactor containing 30L medium, cultivate until just after reaching the logarithmic growth phase (about 8 to 14 hours), add formaldehyde solution with a final concentration of 1.5% to sterilize 1 hours, 4 ° C, 11000 rpm centrifugation, typhoid bacteria (about 200 ~ 300 grams of wet weight), add 2000 ml of 100mM TRIS-HCl (pH 7.5 ~ 8.5, containing 20mM EDTA) buffer to dissolve, electric mixer stirring, Rotate at about 500 rpm, stir for 30 minutes, then add 500 ml of 2.5% sodium deoxycholate (DOC) solution, adjust the rotating speed to about 250-300 rpm, and stir at 4°C for 48-72 hours. Take out the bacterial cell suspension from the 4°C ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

An outer membrane vaccine for preventing the infection of typhoid bacillus and paratyphoid bacillus A and B is disclosed. Its preparing process includes such steps as culturing said bacilli in culture liquid, getting their thallus, and preparing vaccine.

Description

Technical field: [0001] The invention relates to a method for preparing bacterial outer membrane protein from bacterial cells obtained from Salmonella typhi, Salmonella paratyphi A and Salmonella paratyphi B culture fluid, and a vaccine prepared by the method. Background technique: [0002] Typhoid fever and paratyphoid fever are systemic, acute, febrile infectious diseases caused by Salmonella typhi bacilli, type A paratyphi bacilli, and type B paratyphi bacilli that are pathogenic to humans. The main manifestations are persistent high fever, abdominal pain, malaise, headache, and inflammation of the small intestine and colon. Constipation is common in adults and older children, and diarrhea is common in younger children. About 50-70% of patients can isolate typhoid bacilli from feces during the illness period, and even in the convalescent period feces can continue to excrete bacteria, and about 2% of typhoid patients can become chronic carriers. During the excretion perio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/112A61P31/04
CPCY02A50/30
Inventor 孔健蒋先敏黄颖
Owner BEIJING ZHIFEI LVZHU BIOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products